Par Pharmaceutical names new chief commercial officer
WOODCLIFF LAKE, N.J. — Par Pharmaceutical announced the appointment of Antonio R. Pera as CCO. In his new role, Pera will lead Par’s newly integrated sales and marketing organization. He’ll be instrumental in managing Par’s relationships with major trade partners, the company said.
Pera joins the organization from JHP, which Par recently acquired. He has more 30 years of experience in the pharmaceutical industry, which, in addition to his time at JHP, also includes time in executive leadership at AmerisourceBergen Corp.
"Tony has enjoyed a distinguished career in the pharmaceutical industry, and we are very pleased to have him join the Par team," said Paul V. Campanelli, CEO of Par Pharmaceutical Companies. "He has a demonstrated expertise in the marketing, sales and distribution of generic drugs. We look forward to the leadership Tony will provide our commercial organization and the many contributions he will make to our company."
Pera earned an MBA from DePaul University in 1984 and a B.S. in business administration from the University of Illinois, Champaign-Urbana in 1979.
Sam’s Club names new VP health care
BENTONVILLE, Ark. — Sam’s Club has named David Badeen VP health care. Badeen will be responsible for pharmacy, OTC, optical and hearing centers, as well as third party contracting and pricing. In this new role, he will report directly to Jill Turner-Mitchael, SVP health and wellness.
Badeen started his Walmart career in 1985 as a pharmacy manager before moving to Bentonville in 1993 to serve as director of automated systems. He has held leadership roles within the company’s operations, new business development and merchandising and managed care divisions, as well as time working with the Sam’s Club Pharmacy Team.
The company also announced other changes in the division. George Agnacian, VP of consumables, will be responsible for HBA, tabletops/bags, pets, laundry and home care, baby care, restaurant supplies, paper and commercial cleaning.
FDA addresses GDUFA at recent GPhA meeting; association launches online GDUFA resource
ORLANDO, Fla. — Food and Drug Administration Office of Generic Drugs’ acting director Kathleen Uhl on Thursday highlighted the industry and FDA’s shared commitment to Generic Drug User Fee Act milestones and approaching metrics in her keynote address at the GPhA Annual Meeting taking place here.
The Generic Pharmaceutical Association also launched a new digital library and online educational resource, GDUFAnow.org, a new tool to enhance awareness and ease industry familiarity with GDUFA responsibilities, on Thursday.
“GDUFA is a historic achievement and shared commitment for the FDA and our industry,” stated Ralph Neas, president and CEO, GPhA. “GDUFA is supported 100% with industry generated funds. Indeed, efforts to ensure safety, increase access to generics and enhance transparency are top priorities for the Association. This new online resource highlights regulatory developments, compliance requirements and more — putting all of the critical information in one easy to find location.”
As FDA Commissioner Hamburg relayed from India in a recent FDA Voice post: “FDA is working quickly to fulfill one of our commitments under [GDUFA] — reducing the backlog of generic drug applications. As of the end of January 2014, our Center for Drug Evaluation and Research had taken a formal action on 45% of backlogged generic drug applications. In December 2013 alone, the center completed 174 actions, including 30 full approvals for generic drugs. GDUFA also requires that we step up our number of foreign inspections and gives us the funding to do so.”